I

Innovita Biological Technology Co Ltd
SSE:688253

Watchlist Manager
Innovita Biological Technology Co Ltd
SSE:688253
Watchlist
Price: 31.79 CNY -0.63% Market Closed
Market Cap: 4.4B CNY

Innovita Biological Technology Co Ltd
Pre-Tax Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Innovita Biological Technology Co Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
I
Innovita Biological Technology Co Ltd
SSE:688253
Pre-Tax Income
ÂĄ276.5m
CAGR 3-Years
26%
CAGR 5-Years
60%
CAGR 10-Years
N/A
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
Pre-Tax Income
ÂĄ2.4B
CAGR 3-Years
-10%
CAGR 5-Years
0%
CAGR 10-Years
N/A
S
Shanghai Conant Optical Co Ltd
HKEX:2276
Pre-Tax Income
ÂĄ497.4m
CAGR 3-Years
32%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Winner Medical Co Ltd
SZSE:300888
Pre-Tax Income
ÂĄ908.3m
CAGR 3-Years
-15%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
Pre-Tax Income
ÂĄ2.1B
CAGR 3-Years
23%
CAGR 5-Years
18%
CAGR 10-Years
22%
Intco Medical Technology Co Ltd
SZSE:300677
Pre-Tax Income
ÂĄ1.9B
CAGR 3-Years
11%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
No Stocks Found

Innovita Biological Technology Co Ltd
Glance View

Market Cap
4.4B CNY
Industry
Health Care

Innovita Biological Technology Co., Ltd. engages in the research and development, production, and sale of point-of-care testing rapid diagnostic products. The company is headquartered in Beijing, Beijing and currently employs 439 full-time employees. The company went IPO on 2022-07-28. The firm's main products include novel coronavirus (2019-nCoV) neutralizing antibody detection kits using colloidal gold, quantum dot fluorescence immunochromatography and chemiluminescence techniques, and respiratory pathogen detection products, such as whole blood respiratory quintuple detection card, influenza virus triple detection card, virus serum quintuple detection card, respiratory pathogen nine indirect immunofluorescence kit, and others.

Intrinsic Value
25.1 CNY
Overvaluation 21%
Intrinsic Value
Price
I

See Also

What is Innovita Biological Technology Co Ltd's Pre-Tax Income?
Pre-Tax Income
276.5m CNY

Based on the financial report for Dec 31, 2024, Innovita Biological Technology Co Ltd's Pre-Tax Income amounts to 276.5m CNY.

What is Innovita Biological Technology Co Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
60%

Over the last year, the Pre-Tax Income growth was 39%. The average annual Pre-Tax Income growth rates for Innovita Biological Technology Co Ltd have been 26% over the past three years , 60% over the past five years .

Back to Top